Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO, PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 8-WEEK INDUCTION TRIALS (ABTECT-1 & 2) ...
Elis: Disclosure of trading in own shares occured from September 22 to September 25, 2025 Disclosure of trading in own shares occurred from Septembre 22 to September 25, 2025 Saint-Cloud, September 29, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from September 22 to September 25, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer nameIssuer code(L...
Elis : Déclaration des transactions sur actions propres du 22 septembre au 25 septembre 2025 Déclaration des transactions sur actions propres réalisées du 22 septembre au 25 septembre 2025 Saint-Cloud, le 29 septembre 2025 Conformément à la réglementation relative aux rachats d’actions, notamment le Règlement (UE) 2016/1052, Elis déclare ci-après les achats d’actions propres réalisés du 22 septembre 2025 au 25 septembre 2025 dans le cadre du programme de rachat autorisé par la 24ème résolution de l’assemblée générale des actionnaires du 22 mai 2025 et annoncé le 6 mars 2025 : Pré...
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: RESULTS OF 8-WEEK THERAPY IN SUBSETS OF PATIENTS WITH AND WITHOUT PRIOR INADEQUATE RESPONSE TO ADVANCED THERAPIES to be presented Monday, October 6 at 10am CET Abivax manage...
Two Directors at LNA Sante Sa sold/bought 6,900 shares at 29.000EUR. The significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Last week’s EPRA conference provided cautious optimism on listed European real estate. The segment offers a mix of risks and opportunities, with discounted valuations presenting attractive entry points. We downgrade Care Property Invest (Underperform vs Neutral, TP €12 vs €13.5); we lower our TPs for British Land, Landsec, Shurgard, and Xior Student Housing; we raise our TPs for URW, Wereldhave and VGP. In conclusion we favour logistics, retail, Spain, and CEE for growth, and Switzerland remains...
Elis: Disclosure of trading in own shares occured from September 15 to September 19, 2025 Disclosure of trading in own shares occurred from Septembre 15 to September 19, 2025 Saint-Cloud, September 23, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from September 15 to September 19, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer nameIssuer code(L...
Elis : Déclaration des transactions sur actions propres du 15 septembre au 19 septembre 2025 Déclaration des transactions sur actions propres réalisées du 15 septembre au 19 septembre 2025 Saint-Cloud, le 23 septembre 2025 Conformément à la réglementation relative aux rachats d’actions, notamment le Règlement (UE) 2016/1052, Elis déclare ci-après les achats d’actions propres réalisés du 15 septembre 2025 au 19 septembre 2025 dans le cadre du programme de rachat autorisé par la 24ème résolution de l’assemblée générale des actionnaires du 22 mai 2025 et annoncé le 6 mars 2025 : Pré...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.